Agreement - January 29, 2020
SAGA Diagnostics extends collaboration with Servier
SAGA Diagnostics has entered service agreements with the international pharmaceutical company Servier, based in Paris, France. “These deals exemplify the increased demand we are experiencing for our offerings of ultrasensitive cancer analysis services and analysis kits. We are excited to be working with Servier, who continues to choose us for important translational oncology projects,” says […]
Agreement - January 28, 2020
Scandinavian Biopharma expands its Nordic vaccine business
Scandinavian Biopharma has entered into a Nordic distribution agreement with Emergent Travel Health for the oral typhoid vaccine Vivotif. Typhoid fever is a severe and potentially life-threatening infection caused by the Salmonella bacteria. Since 1st of January 2020 Scandinavian Biopharma is the local representative for Vivotif in Sweden, Norway, Denmark and Finland. “We are really […]
Agreement - January 27, 2020
AstraZeneca to recover the global rights to brazikumab
AstraZeneca will recover the global rights to brazikumab (formerly MEDI2070), a monoclonal antibody targeting IL23, from Allergan. Brazikumab is currently in a Phase IIb/III programme in Crohn’s disease (CD) and a Phase IIb trial in ulcerative colitis (UC). Expected to complete in the first quarter of 2020 AstraZeneca and Allergan will terminate their existing license agreement and […]
Agreement - January 16, 2020
Microsoft and MSD in strategic partnership for Nordic and Baltic life science
The two companies have agreed on a partnership for the Nordic and Baltic markets with the aim to support healthcare. One possible field of cooperation is the use of cutting-edge technique, such as artificial intelligence, to support early diagnosis for i.a. lung cancer, they state. “The Nordic and Baltic states are at the forefront of […]
Agreement - January 13, 2020
Coala-Life and Asahi Kasei enter technology partnership in Japan
Coala Life has announced a research and development partnership with Asahi Kasei Corporation in Japan. The collaboration includes a development program and research targeting Heart Failure (HF) patients in Japan. Exclusively on the Japanese market Coala Life has partnered with Asahi Kasei Corporation exclusively on the Japanese market to further develop and evaluate the use of […]
Agreement - December 19, 2019
Recipharm partners with Aptahem
Recipharm has partnered with biotechnology company Aptahem, for the formulation of Apta-1 drug candidate. The aptamer-based drug candidate is intended to treat life-threatening condition sepsis, a potentially fatal condition which involves a general inflammatory response, known as systemic inflammatory response syndrome (SIRS), caused by an infection. Recipharm will develop an injectable formulation for the upcoming […]
